

Supplementary Table 1. Patient characteristics and disposition

Characteristic	Early combination (n=22)	Initial monotherapy (n=17)	Total (n=39)
Women	11 (50.0)	8 (47.1)	19 (48.7)
Age, yr			
Mean	52.8±8.6	52.8±10.2	52.8 (9.2)
Median	53.5 (46.0–59.0)	54.0 (49.0–58.0)	54.0 (46.0–59.0)
<51	6 (27.3)	7 (41.2)	13 (33.3)
51–≤59	10 (45.5)	5 (29.4)	15 (38.5)
>59	6 (27.3)	5 (29.4)	11 (28.2)
Race			
Asian	20 (90.9)	17 (100.0)	37 (94.9)
Other ^a	2 (9.1)	0	2 (5.1)
Median duration of T2DM, mo	3.2 (0.8–8.0)	1.7 (1.1–9.0)	3.1 (0.8–8.8)
HbA1c, % ^b			
Mean	6.7±0.4	6.8±0.4	6.7 (0.4)
Median	6.7 (6.4–6.9)	6.7 (6.6–7.1)	6.7 (6.5–7.0)
<7.0%	17 (77.3)	11 (64.7)	28 (71.8)
≥7.0%	5 (22.7)	6 (35.3)	11 (28.2)
Median FPG, mmol/L ^b	6.4 (5.9–7.3)	6.9 (6.6–7.1)	6.7 (6.2–7.3)
BMI, kg/m ²			
Mean	26.2±3.0	26.5±2.1	26.3 (2.6)
Median	25.6 (24.3–27.9)	26.5 (25.3–27.4)	26.1 (24.8–27.5)
<25	7 (31.8)	4 (23.5)	11 (28.2)
≥25	15 (68.2)	13 (76.5)	28 (71.8)
eGFR ^c , mL/min/1.73 m ²			
Normal (>80)	16 (72.7)	13 (76.5)	29 (74.4)
Mild (≥50–≤80)	6 (27.3)	4 (23.5)	10 (25.6)
Moderate (≥30–<50)	0	0	0
Severe (<30)	0	0	0
Median weight, kg	70.5 (60.0–79.0)	69.0 (68.3–73.0)	69.0 (63.9–77.7)
Current smoker			
Yes	3 (13.6)	1 (5.9)	4 (10.3)
Discontinued study participation prematurely	8 (36.4)	3 (17.6)	11 (28.2)
Administrative problems	6 (27.3)	0	6 (15.4)
Investigator decision	1 (4.5)	0	1 (2.6)
Individual patient decision	2 (9.1)	0	2 (5.1)
Relocation of patient to another country	1 (4.5)	0	1 (2.6)
Personal reasons	2 (9.1)	0	2 (5.1)
Lost to follow-up	1 (4.5)	1 (5.9)	2 (5.1)
Protocol deviation	1 (4.5)	0	1 (2.6)
Unsatisfactory therapeutic effect	0	1 (5.9)	1 (2.6)
Patient withdrew consent	0	1 (5.9)	1 (2.6)

Values are presented as number (%), mean±standard deviation, or median (interquartile range). Baseline refers to randomization visit. Ethnicity did not include Hispanic or Latino, Chinese, Indian, or Mixed.

T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; BMI, body mass index; eGFR, estimated glomerular filtration rate. ^aTwo patients were of Korean mixed race, so were not included in the predominant race category and were denoted as 'others'. ^bBaseline values were obtained on screening (day 1) or at a later visit (scheduled or unscheduled) if the day 1 measurements were missing. Two patients in the early combination therapy group did not have baseline HbA1c and fasting plasma glucose measurements on or prior to randomization. ^cBaseline eGFR was calculated using the Modification of Diet in Renal Disease Study equation. Serum creatinine and body weight measurements were obtained on day 1 or at a later visit (scheduled or unscheduled) if the day 1 measurements were missing.